Respiratory Syncytial Virus (RSV) — Brookshire's

Fact checked by Robert Carlson, MD

Sep 5

3 min read

FDA Breakthrough Therapy Designation Granted for Respiratory Syncytial Virus Vaccine

Janssen Ad26.preF based RSV vaccine candidate launched a phase 2b clinical study

older man contemplating

Respiratory Syncytial Virus (RSV)

Fact checked by Robert Carlson, MD

Aug 15

3 min read

ResVax Demonstrated Significant Vaccine Efficacy Against Infant Pneumonia Early in Life

Novavax ResVax is an aluminum adjuvanted respiratory syncytial virus fusion protein recombinant nanoparticle vaccine

happy little girl with dad

Respiratory Syncytial Virus (RSV)

Fact checked by Robert Carlson, MD

Aug 1

6 min read

Longhorn & NIH Leading Innovative RSV Vaccine Study

DS-Cav1 vaccine candidate elicited large increases in RSV-neutralizing antibodies sustained for several months

grandpa holding a sleeping grandchild

Respiratory Syncytial Virus (RSV)

Fact checked by Robert Carlson, MD

Jun 10

4 min read

ResVax Vaccine Continues to the RSV Finish Line

Novavax ResVax vaccine candidate is an RSV fusion protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant

new born baby feet in a basket

Respiratory Syncytial Virus (RSV)

Fact checked by Kelley Lu, PharmD

Mar 27

5 min read

Insights for Developing RSV Vaccines

Synagis needs to provide both the antiviral activity and a countermeasure to the viral distortion of the host immune response

Respiratory Syncytial Virus (RSV)